NEWMEDS - Novel Methods leading to New Medications in Depression and Schizophrenia - is an international consortium of scientists that has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia and depression.
NEWMEDS brought together top scientists from academic institutions with a wide range of expertise, and partners them with nearly all major biopharmaceutical companies. The project has focussed on developing new animal models which use brain recording and behavioural tests to identify innovative and effective drugs for schizophrenia. NEWMEDS has developed standardised paradigms, acquisition and analysis techniques to apply brain imaging, especially fMRI and PET imaging to drug development. It has examined how new genetic findings (duplication and deletion or changes in genes) influence the response to various drugs and whether this information can be used to choose the right drug for the right patient. And finally, it has developed new approaches for shorter and more efficient trials of new medication – trials that may require fewer patients and give faster results.
Please press start to view a short film during the Final Meeting on the legacies of the project.